

Molecular Detection of Quinolones Resistance Gens of *Salmonella* Typhi from Gallbladder of Patients Undergoing to Cholecystectomy in Thi-Qar province/Iraq

ZAMAN K. HANAN¹, EZAT H. MEZAL², MANAL B.SALEH¹

¹Department of Biology - Collage of science – University of Thi-Qar. Iraq

²Collage of Nursing – University of Thi-Qar. Iraq

Corresponding email: zaman.K_bio@sci.utq.edu.iq

ABSTRACT

Salmonellaenterica serovar Typhi chronically persists within the gallbladder and it may be a predisposing factor for gallbladder diseases. Thus, it is necessary to screen such carriers and understand their distribution within a population with high incidences of gallbladder diseases. This study aimed to focus on determining the actions used by *S.Typhi* to allow chronic carriage in the gallbladder and try to demonstrate that *S.Typhi* may have a causal role in gallbladder diseases. Antibiotic treatment of chronic *S.Typhi* is difficult compared to treatment of acute infection. In the present study, the detection of their antibiotic resistance against 16 antibiotics of different classes showed that all isolates were sensitive to tigracycline and levofloxacin and whereas all isolates were resistances to ampicillin and cefazolin; the most prevalent pattern included resistance to gentamycin, ciprofloxacin, amikacin, cefoxitin, piperacillin/ tazobactam and cefepime (90.9, 81.8, 63.6, 63.6, 54.5, and 54.5)% respectively. The percentage of multidrug-resistant (MDR) was high, more than (90%) and screening of quinolones-resistance genes (*qnrB* and *qnrS*) among the *S.Typhi* showed *qnrS*- and *qnr-B* gene were identified in (65.4%) and (46.2%) respectively.

Keywords: Gallbladder diseases, *Salmonella* Typhi, Quinolones Resistance

1. Introduction

The gallbladder is one part of the biliary tract; it's a pear-shaped hollow organ; located in a very region on the posterior surface of the right lobe, the length its 7-10 cm with a width around 3 cm and Its work to store and gradually release bile into the digestive system for fat digestion, Bile is emitted into the stomach for digestion from the liver and gallbladder (Halgaonkar *et al.*, 2016). The gallbladder diseases are including cholelithiasis (gallstone disease "GS") which is the presence of stones

within the gallbladder or the duct resulting in pain and discomfort within the abdomen; GS is a significant concern for health services nationwide and is one of the most prevalent conditions in patients with abdominal pain in emergency departments (Dhamnetiya *et al.*, 2018). Another disease is cholecystitis that's inflammation of the gallbladder could be acute or chronic has been caused by biliary tract obstruction due to the presence of gallstones (Wistuba & Gazdar, 2004). In addition to gallbladder carcinoma (GC), the most typical extrahepatic biliary tract malignancy is an aggressive malignancy and the world's most widespread biliary tract tumor with the highest occurrence and mortality rates in Northern India (Randi *et al.*, 2006). The human's bile is taken into account to be an antimicrobial agent because of its properties as detergent in addition to its role in aiding in fat digestion, consequently, that bile prevents the expansion of invading pathogens within the duct thus acting as a defense barrier (Hall-Stoodley & Stoodley, 2009). Although certain bacteria have been evolved resistance to antibacterial effects of bile and they could grow selectively on the media containing bile salts such as (*Salmonella-Shigella* agar and MacConkey agar). Interestingly, bile is additionally showed to regulate certain bacterial genes expression which is necessary for bile resistance and pathogenesis (Hernandez *et al.*, 2012). Different microbiological and molecular methods were used to show the the presence of different bacteria in the gallbladder or hepato-biliary tree such as *Enterococcus* spp., *Escherichia* spp., *Streptococci* spp., *Klebsiella* spp., *Enterobacter* spp., *Citrobacter* spp., *Proteus* spp., *Staphylococcus* spp., *Pseudomonas* spp., *Acintobacter* spp. and *Salmonella* spp. (Arteta *et al.*, 2017). *Salmonella enterica* consists of more than 2668 serovar. It can cause disease in both humans and animals (Saleh *et al.*, 2016). It will invade the body by infected food and water; the epithelium of the small intestine may be inserted within the intestines or penetrated to enter the bloodstream such that it may spread to the liver, gallbladder, spleen, lungs and other organs (Harvey *et al.*, 2013). The bacteria *Salmonella enterica* serovar Typhi (*S. Typhi*), the etiologic agent of typhoid fever, causes about 20 million infections each year worldwide (Dougan & Baker, 2014). The clinical symptom of typhoid fever is persistent fever, stomach pain, fatigue and general lethargy. The involvement of distinct protective, as well as offensive virulence factors is consistent with the complex pathogenesis of systemic *Salmonella* infections. As an intracellular human pathogen, these factors contribute to its success and participate in multiple stages of invasion, intracellular reproduction and survival within the host. When *S. Typhi* enters

the gallbladder and causes an acute infection amid cholecystitis or act as an asymptomatic carrier state to mediate colonization in the gallbladder by this mechanism utilized by the bacterium caused gallbladder abnormalities, especially gallstones (Gunn *et al.*, 2014). Many studies in endemic regions showing a strong link between bacterial colonization in gallbladder and the presence of gallbladder diseases. Furthermore, other studies reveal that chronic *S. Typhi* persistence can be considered as one of the predisposing factors for gallbladder cancer. However, a variety of mechanisms for carcinogenesis in chronic typhoid carriers has been postulated. Colonization of the gallbladder and chronic presence of *S. Typhi*, which is the most effective parameter on the surface of the gallstone, tends to be favored by biofilm formation. The ability to form multilayer biofilm is an essential factor for the virulence of *S. Typhi* and has been shown to promote the survival when they were being exposed to host immunity or antibiotic treatment (Hamilton *et al.*, 2009; Fàbrega & Vila, 2013). Characterization of the molecular processes involved in the creation of biofilms on biliary stones and the activity of *S. Typhi* remains to be further studied in the promotion of gallbladder inflammation and injury. Clinically prescribed antibiotics are usually ineffective against chronic bacterial infection of the gallbladder in patients who have gallstones with both *S. Typhi* and cholesterol (Crawford *et al.*, 2008) and the treatment with antibiotics is always unsuccessful in eradicating biofilm-associated bacteria (Zimmerli *et al.*, 2004); once the biofilm is formed, there is an improved susceptibility of individual cells to antimicrobial agents, and antibiotic treatment alone is always insufficient (Hengzhuang *et al.*, 2012). The aims of this study are to explore the antimicrobial resistance profile *in-vitro* and detection of some quinolone resistance genes in *S. Typhi* from gallbladder diseases patients.

2. MATERIALS AND METHODS

2. Screening and Characterization of *S. Typhi* Persisting in Gallbladder of Patients Undergoing Cholecystectomy

2.1 Bacterial cultures

All fresh specimens (bile, gallstones, mucosa and gallbladder sac samples) (n=50) were cultured aerobically by weighing out 25 g specimens into an Erlenmeyer flask containing 225 ml of buffered peptone water to obtain 1 part sample + 9 part buffer then mixed and incubated at 37°C overnight (16-20 hours) then transfer 1 ml of from the

inoculated and incubated buffered peptone water with a sterile pipette to 10 ml Tetrathionate broth (Müller-Kauffmann). Incubate at $41.5^{\circ}\text{C} \pm 0.5^{\circ}\text{C}$ overnight (18-24 hours), Spread a 10 μl loop full from the inoculated and incubated Tetrathionate broth on XLD and on BGA agar plates and incubate at 37°C overnight (18-24 hours) and read the XLD plates and BGA plates. *Salmonella* spp. suspect colonies on XLD and BGA agar onto non-selective media, (nutrient agar) plates for biochemical confirmation of *Salmonella* spp.

2.2 Biochemical tests:

The important biochemical tests were conducted these tests include {Triple Sugar Iron (TSI) and Kligler iron (KI), Catalase test, Oxidase test, Lactose fermentation, Urease test, Indole test, Citrate utilization test} (Cappuccino & Sherman, 2017).

2.3 Api-20E system (Analytical profile index for Enterobacteriaceae test)

Api-20E system is used clinically for the rapid identification of the *Salmonella* Typhi isolates this test done according to Leboffe and Piercer, (2005)

2.4 VITEK-2 compact system (Pincus, 2010)

Salmonella Typhi which identified by morphological, biochemical tests and Api-20E system are subjected to the automated VITEK-2 compact system (VITEK-2 GNID kit) was employed in bacterial diagnosis, screened for their antibiotic resistance against 16 antibiotics of various classes.

2.5 Detection of Quinolones Resistance Genes

Quinolones resistance genes (*qnr-B* and *qnr-S*) as in table (1) of *S. Typhi* were detected by Multiplex PCR. Total DNA (2 μl) was subjected to multiplex PCR in 23 μl reaction mixture containing 1X PCR Buffer [10 Mm Tris-HCl (pH 8.3), 50 Mm KCl, 1.5 Mm MgCl_2 , 200 Mm of each deoxynucleotide triphosphate, 2.5 U of Taq polymerase], 2 μl of each of the four primers and 14 μl of nuclease free water. Amplification was carried out with thermal cycling profile in PCR condition as explained in Table (2) and the products of PCR were visualized by electrophoresis

Table (1): Primers that used for detection of quinolones resistant genes (*qnrB* & *qnrS*) (Bioneer/ Korea)

Gene name	DNA Sequences (5'-3')	Product Size(bp)	Reference
-----------	-----------------------	------------------	-----------

<i>qnr-B</i>	F	5'-GGMATHGAAATTCGCCACTG -3'	264	(Cattoir <i>et al.</i> ,2007b)
	R	5'-TTTGCGYGYCGCCAGTCGAA-3'		
<i>qnr-S</i>	F	5'-GCAAGTTCATTGAACAGGCT-3'	428	(Cattoir <i>et al.</i> ,2007a)
	R	5'-TCTAAACCGTCGAGTTCGGCG-3'		

* H= A or C or T; Y= C or T

Table (2):- Thecondition PCR for quinolones resistant genes amplification

stage	Step	T (° C)	Time (min)	Number of Cycles
I	Initial Denaturation	95	10	1
II	I Denaturation	95	1	35
	II Annealing	54	1	
	III Extension	72	1	
III	Final Extension	72	10	1

3. RESULTS

A total of 200 samples of gallbladder of GD patients, only 26 samples were positive for *S.Typhitis* is about 13% of patients as show in Figure (1). These were diagnosed by molecular methods to identification genes "*invA*, *viaB* and *H1d*" as illustrated in Figure (1).




Figure (1): Occurrence of *S. Typhi* in GD patients

Antimicrobial susceptibility test of the 11 isolates are summarized in Figure (2). The table indicated that the degree of susceptibility varied and all isolates were sensitive to tigecycline and levofloxacin. On the other hand all isolates were resistances to ampicillin and cefazolin; the foremost prevalent pattern included resistance to gentamicin ciprofloxacin, amikacin, ceftazidime, piperacillin/tazobactam and cefepime (90.9, 81.8, 63.6, 63.6, 54.5 and 54.5) % respectively. The resistances to ceftriaxone, ceftazidime and trimethoprim/ sulfamethoxazole were (45.4%) of isolates, while only (36.36, 36.36 and 18.1) % of isolates were resistances to nitrofurantoin, imipenem and erapenem respectively; while (36.36, 27.2 and 9.09) % of isolates were intermediate to nitrofurantoin, cefepime and ciprofloxacin respectively.




Figure (2): Susceptibility of *S. Typhi* isolates (n=11) to antimicrobial agent

The present study showed an increase in the incidence of multiple drug resistant (MDR), the proportion of multidrug-resistant (MDR) bacteria was high. Ten (90%) isolates considered as multi-drug resistant because the isolates were totally resistance to equal or more than one antibiotic in equal or more than three antimicrobial categories. One isolate was resistant to 11 antibiotics, three isolates were resistant to 10 antibiotics, two isolates were resistant to 9 antibiotics and one isolate was resistant to 8 antibiotics; while three isolates were resistant to 7 antibiotics as shown Figure (3).




Figure (3):MDR in *S.Typhi* isolates (n=11)

Screening for quinolones-resistance genes (*qnrB* and *qnrS*) among the *S.Typhi* included in this study was achieved by a multiplex PCR; overall, *qnrS*- gene were identified in 17/26 (65.4 %) of *S.Typhi*. while 12/26(46.2 %) were positive for *qnrB*- gene as appeared in Figure (4).The *qnr-B* gene was absent in half cancerous patients and all a.a.cholecystitis patients, while 52.4% of GS patients contain this gene;




Figure (4): PCR products of the *qnr-B* & *qnr-S* genes of *S. Typhi*, The size of the PCR product is 428 bp and 264 bp respectively. The gel was 1.5% and the DNA dye is RedSafe (Intron, Korea). V: 95, Time: 45 minutes. M: Marker DNA ladder (100-2000) bp; (1-15): *S. Typhi*

4. DISCUSSION

Currently, removal of the gallbladder is only cure for chronic *S.Typhi* infection but does not ensure removal of bacteria persisting in ,additional foci within the body and antibiotic treatment of chronic *S.Typhi* persisting in the gallbladder is difficult compared to treatment of acute infection and less than two-thirds of the chronic infections are resolved with prolonged high-dose antibiotic therapy that is associated with side effects like gastric discomfort and gastrointestinal bleeding (Gonzalez-Escobedo *et al.*, 2011). In present research, the resistance to common antibiotics used in the treatment of *S.Typhi* was tested and appeared all the

chronically persisting isolates of *S.Typhi* obtained from the gallbladder showed resistance ampicillin and cefazolin, gentamycin and high resistance to ciprofloxacin, amikacin, piperacillin/tazobactam, and ceftiofur; these results agree with Al-aarajy, (2020) was found all isolates were resistant to four or more classes of antibiotics as antimicrobials. Although, AlObaidiet *al.*, (2019) appeared that samples of *S.Typhi* demonstrated total resistance to gentamicin and ciprofloxacin, moderate sensitivity to trimethoprim and complete resistance to amoxicillin and piperacillin. These differences between studies because AlObaidi's isolates were from diarrheal patients in Al-Najaf governorate, whereas, our bacterial isolates were from gallbladder, as the presence of harsh conditions represented by the presence of bile. However, Song *et al.*, (2010) proved the treatment with ampicillin is only effective in patients without gallstones, while Pratap *et al.*, (2012); showed all the chronically persisting isolates of *S.Typhi* obtained from the gallbladder were resistant to common first-line antibiotics aside from ampicillin, here, our results demonstrated that *S.Typhi* was biofilm formation so that was more resistant to ciprofloxacin these findings agree with a study by Parry & Threlfall, (2008) which appeared more resistant to ciprofloxacin in biofilm formation isolates; However, a fluoroquinolone antibiotic is commonly used to treat *Salmonella* infections. By the altering drugs targets, reducing drugs, accumulation, shielding drug targets and enzymatic drug modification several gram-negative bacteria can resist quinolones (McDermott *et al.*, 2003). Also, chromosomal mutations in genes that code for topoisomerase IV and DNA gyrase and genes code for outer membrane and efflux proteins are largely responsible for this resistance, *qnr* proteins protecting DNA gyrase and topoisomerase-IV from quinolones (Robicsek *et al.*, 2006). On a wide scale, Touati *et al.*, (2008) determinants of *Qnr* have been found in North and South America, Europe, Africa and Asia. They've been included in several different Enterobacteriaceae species such as *E. coli*, *Enterobacter spp.*, *Klebsiella spp.*, *Salmonella spp.*, *Providencia stuartii*, *Proteus mirabilis* and *Serratia marcescens* (Cambau *et al.*, 2006). According to the present results, percentage of (81.8) % of the isolates was resistant to ciprofloxacin. So that investigated the presence of *qnr* genes among *S.Typhi* were essential and showed there were 17 positive results to *qnrS* and 12 positive results for *qnrB*, while 10 were carry both *qnr* resistance genes. The domination of the *qnrS* and *qnrB* genes in present research is close to the European study by Poirel *et al.*, (2006). Similarly, in

the study by Mohammad, (2017) was found quinolones resistance gene in gram-negative bacteria were high in clinical isolates. In addition, Le Hello *et al.*, (2013) explained that some plasmid-mediated genes which coded for DNA topoisomerase protecting proteins responsible for quinolone resistance in *Salmonella*. The emergence of widespread multidrug resistance (MDR) among *Salmonella* strains could have a significant impact on public health (Parsons *et al.*, 2013). Due to the continuous rise in the MDR in *S. Typhi* especially in carriers state, so that, it is difficult to treat such infections. The present research showed increasing in the incidence of MDR and the proportion of MDR was over (90%). These results resemble to the findings of other researchers like El-Ma'adhidi, (2004) and Misra *et al.*, (2005). Worldwide, Emborg *et al.*, (2003) reported during the last decades, the uncontrolled using of antimicrobial agents for growth promotion, treating patient, veterinary fields and prevention in conventional food production have led to the event of antibiotic resistance in *Salmonella*.

Conclusion:-

1. From the analysis of the drug susceptibilities of the isolates, it was seen that all isolates were sensitive to tetracycline and levofloxacin whereas all isolates showed resistance to ampicillin and cefazolin and high in resistance to gentamycin, ciprofloxacin, amikacin, piperacillin/tazobactam and ceftiofur and more than 90% of all the assessed isolates were MDR.
2. Quinolones resistance rates in *S. Typhi* were high and the most of the resistance isolates harboring *qnr-S* gene

REFERENCES

1. **Al-aarajy, A. Nabeel (2020).** Assessment of Silver Nanoparticles as Anti-*Salmonella* Agent: Phenotypic, Genotypic and Histological Study .Thesis Degree of Doctorate of Philosophy of College of Science- University of Anbar.
2. **AlObaidi Ahmed Flyyih; Mohammed N. T.; Abdulrazzaq Mohammed and Basim Basima (2019)** .Molecular detection of *Salmonella typhi* isolated from diarrheal patients in Al- Najaf governorate .*Annals of Tropical Medicine & Public Health* .22(9).

3. **Arteta, A. A.; Carvajal-Restrepo, H.; Sánchez-Jiménez, M. M.; DíazRodríguez, S. and Cardona-Castro, N. (2017)** .Gallbladder microbiota variability in Colombian gallstones patients .*The Journal of Infection in Developing Countries* .11(03): 255-260.
4. **Cambau, E.; Lascols, C.; Sougakoff, W.; Bebear, C.; Bonnet, R.; Cavallo, J. D. and Robert, J. (2006)** . Occurrence of qnrA-positive clinical isolates in French teaching hospitals during 2002–2005. *Clinical microbiology and infection*, 12(10), 1013-1020.
5. **Cappuccino, J. G. and Sherman, N. (2005)** .Microbiology: a laboratory manual.
6. **Cattoir, V.; Poirel, L.; Rotimi, V.; Soussy, C. J.; Nordmann, P. (2007a)** . Multiplex PCR for detection of plasmid-mediated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates. *Journal of antimicrobial chemotherapy*, 60(2), 394-397.
7. **Cattoir, V.; Weill, F. X.; Poirel, L.; Fabre, L.; Soussy, C. J. and Nordmann, P.(2007b)** .Prevalence of qnr genes in *Salmonella* in France. *Journal of Antimicrobial Chemotherapy*, 59(4), 751-754.
8. **Crawford, R. W.; Gibson, D. L.; Kay, W. W. and Gunn, J. S. (2008)** .Identification of a bile-induced exopolysaccharide required for *Salmonella* biofilm formation on gallstone surfaces .*Infection and immunity* .76(11), 5341-5349.
9. **Dhamnetiya, D.; Goel, M. K.; Dhiman, B. and Pathania, O. P. (2018)** .Gallstone disease and quantitative analysis of independent biochemical parameters: Study in a tertiary care hospital of India .*Journal of laboratory physicians* .10(4), 448.
10. **Dougan, G. and Baker, S. (2014).** *Salmonella enterica* serovar Typhi and the pathogenesis of typhoid fever. *Annual review of microbiology*, 68, 317-336.
11. **Emborg, H. D. ; Anderson, J. S. ; Seyfarth, A. M. ; Andersen, S. R. ; Boel, J. and Wegener, H. C. (2003).** Relation between the occurrences of resistance to antimicrobial growth promoters among *Enterococcus Faecium* isolated from broiler and broiler meat. *International Journal Food Microbiology* .84: 273 – 284.
12. **Fàbrega, A. and Vila, J.(2013)** .*Salmonella enterica* serovar Typhimurium skills to succeed in the host: virulence and regulation. *Clinical microbiology reviews*, 1; 26(2):308-41.

13. **Gonzalez-Escobedo, G.; Marshall, J. M. and Gunn, J. S. (2011)** .Chronic and acute infection of the gallbladder by *Salmonella* Typhi: understanding the carrier state. *Nature Reviews Microbiology*, 9(1), 9-14.
14. **Gunn, J. S.; Marshall, J. M.; Baker, S.; Dongol, S.; Charles, R. C. and Ryan, E. T. (2014)** .*Salmonella* chronic carriage: epidemiology, diagnosis, and gallbladder persistence. *Trends in microbiology*, 22(11), 648-655.
15. **Halgaonkar, P.; Verma, R.; Bhadre, R.; Unadkat, P.; Vaja, C. and Unadkat, P. (2016)** .Study to establish the clinical correlation between chemical constituents of gallstones and serum biochemical parameters .*International Journal of Scientific Study* .4(3), 97-102.
16. **Hall-Stoodley, L. and Stoodley, P.(2009)**.Evolving concepts in biofilm infections. *Cellular microbiology*, 11(7), 1034-1043.
17. **Hamilton, S.; Bongaerts, R. J.; Mulholland, F.; Cochrane, B.; Porter, J.; Lucchini, S. and Hinton, J. C.(2009)**.The transcriptional programme of *Salmonella enterica* serovar Typhimurium reveals a key role for tryptophan metabolism in biofilms. *BMC genomics*, 10(1), 1-21.
18. **Harvey R. A.; Cornelissen, C. N. and Fisher, B. D.(2013)** .Lippincott's Illustrated Review of Microbiology .3th Edn ., Lippincott William & Wilkins , a Wolters Kluwer Health, China.
19. **Hernández, S. B.; Cota, I.; Ducret, A.; Aussel, L. and Casadesús, J. (2012)** .Adaptation and preadaptation of *Salmonella enterica* to bile .*PLoS Genet* .8(1), e1002459.
20. **Le Hello, S.; Harrois, D.; Bouchrif, B.; Sontag, L.; Elhani, D.; Guibert, V. and Weill, F. X. (2013)** .Highly drug-resistant *Salmonella enterica* serotype Kentucky ST198-X1: a microbiological study. *The Lancet infectious diseases*, 13(8), 672-679.
21. **Leboffe, M. and Pierce, B. (2005)** .A photographic atlas for the microbiology laboratory 3rd Edition.
22. **Mc Dermott, P. F.; Walker, R. D. and White, D. G. (2003)** .Antimicrobials: modes of action and mechanisms of resistance. *International journal of toxicology*, 22(2), 135-143.
23. **Mohammed. M. A. (2017)** .Detection of Quinolones Resistance among Gram Negative Bacteria Isolated from Clinical Samples .A Thesis for master in College of Science-University of Thi-Qar.

24. **Parry, C. M. and Threlfall, E. J. (2008)** .Antimicrobial resistance in typhoidal and nontyphoidal *Salmonellae* .*Current opinion in infectious diseases* .21(5), 531-538.
25. **Parsons, B. N., Crayford, G., Humphrey, T. J., & Wigley, P. (2013)** .Infection of chickens with antimicrobial-resistant *Salmonella enterica* Typhimurium DT193 and monophasic *Salmonella* Typhimurium-like variants: an emerging risk to the poultry industry? *Avian Pathology* .42(5), 443-446.
26. **Pincus, D. H.(2006)** .Microbial identification using the bioMérieux Vitek® 2 system. *Encyclopedia of Rapid Microbiological Methods* .Bethesda, MD: Parenteral Drug Association .1-32.
27. **Poirel, L.; Leviandier, C. and Nordmann, P. (2006)** .Prevalence and genetic analysis of plasmid-mediated quinolone resistance determinants QnrA and QnrS in Enterobacteriaceae isolates from a French university hospital . *Antimicrobial agents and chemotherapy*, 50(12), 3992-3997.
28. **Pratap, C. B.; Patel, S. K.; Shukla, V. K.; Tripathi, S. K.; Singh, T. B. and Nath, G. (2012)**. Drug resistance in *Salmonella enterica* serotype Typhi isolated from chronic typhoid carriers. *International journal of antimicrobial agents* .40(3), 279-280.
29. **Randi, G.; Franceschi, S. and La Vecchia, C. (2006)** .Gallbladder cancer worldwide: geographical distribution and risk factors .*International journal of cancer* .118(7), 1591-1602.
30. **Robicsek, A.; Jacoby, G. A. and Hooper, D. C.(2006)** .The worldwide emergence of plasmid-mediated quinolone resistance. *The Lancet infectious diseases* .6(10), 629-640.
31. **Saleh, B. Manal; Mezal, H. Ezat; Hanan K. Zaman(2016)** .Antimicrobial resistance, Virulence profiles of *Salmonella enterica* serovar Typhimurium isolated from diarrheal children in Thi-Qar province during 2015 *Journal of Thi-Qar science* .No.1.
32. **Song, J.; Willinger, T.; Rongvaux, A.; Eynon, E. E.; Stevens, S.; Manz, M. G. and Galán, J. E.(2010)**.A mouse model for the human pathogen *Salmonella* typhi. *Cell host & microbe* .8(4), 369-376.
33. **Touati, A.; Brasme, L.; Benallaoua, S.; Gharout, A.; Madoux, J. and De Champs, C. (2008)** .First report of qnrB-producing *Enterobacter cloacae* and

qnrA-producing *Acinetobacter baumannii* recovered from Algerian hospitals. *Diagnostic microbiology and infectious disease* .60(3), 287-290.

34. **Wistuba, I. I. and Gazdar, A. F. (2004)** .Gallbladder cancer: lessons from a rare tumour. *Nature Reviews Cancer* .4(9), 695-706.
35. **Zimmerli, W.; Trampuz, A. and Ochsner, P. E.(2004)**. Prosthetic - joint infections. *New England Journal of Medicine* .351(16), 1645-1654.